로딩 중…
지수 로딩 중…
HANALL BIOPHARMA CO.,LTD
009420· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩50,800-7.47%
2026-06-19
Price Chart
HANALL BIOPHARMA CO.,LTD+97.28%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 2.65T KRW |
| Revenue | 159.06B KRW |
| Net Income | -5.77B KRW |
| Total Assets | 243.83B KRW |
| Net Assets | 162.36B KRW |
| Employees | 318 |
| Value | |
| P/B | 16.35x |
| P/S | 16.68x |
| FCF Yield | -0.12% |
| Profitability | |
| ROE | -3.55% |
| ROA | -2.37% |
| Op. Margin | -0.49% |
| Revenue Growth | 10.73% |
| Earnings Growth | -485.74% |
| Financial Health | |
| Debt Ratio | 150.18% |
| Total Debt | 43.17B KRW |
| FCF | -3.29B KRW |
| Cash | 36.16B KRW |
| Current Ratio | 1.60x |
| Performance | |
| 1Y Return | 97.28% |
| 1M Return | 29.59% |
| From 52W High | -30.41% |
| 1Y MDD | -39.13% |
| Trading | |
| Volume | 371,011 shares |
| Foreign Own. | 4.47% |
| Per Share | |
| EPS | -97 KRW |
| BPS | 3,197 KRW |
Company Info
Hanall Biopharma is a pharmaceutical company established in 1973 and listed on the Korea Exchange in 1989. It manages overseas clinical trials and licensing for new drugs through its U.S. subsidiary, HPI. The company manufactures and sells over 160 pharmaceutical products for endocrine, circulatory, and other systems, while researching diverse new drugs, including antibody-based therapies for autoimmune diseases. By strengthening its R&D infrastructure with First-in-Class biosimilar drug research, dedicated personnel, and expanded facilities, Hanall Biopharma is enhancing its global market competitiveness. It is headquartered in Daedeok-gu, Daejeon.